Skip to main content

PINNACLE-AF Registry Suggests Slow Uptake of New Anticoagulants


August 16, 2012 (Washington, DC) — Preliminary data from the PINNACLE registry focusing on patients with atrial fibrillation (AF) suggest that just under half of patients with AF are treated with anticoagulants [1]. Interestingly, of patients in the registry who received oral anticoagulation, 87.4% were treated with warfarin in 2011 while just 12.6% were prescribed one of the two newly available oral anticoagulants.
"We were a little bit surprised," said Dr William Oetgen (Georgetown University, Washington, DC) in reference to the relatively high number of patients who remained on warfarin. "The efficacy and the safety of the novel oral anticoagulants, the two of them that are on the market, are better than Coumadin. The ease of administration is much better than Coumadin. . . . On balance, the drugs seem to be a therapeutic advancement, but the uptake has been slower than we thought it would be."
The PINNACLE-AF registry is part of the American College of Cardiology (ACC) National Cardiovascular Data Registry (NCDR) and is designed to determine how the next generation of anticoagulants is being used in clinical practice. Like PINNACLE, which is the largest cardiovascular outpatient database in the US, the PINNACLE-AF registry is focused on improving quality of care and clinical outcomes in patients with AF. As reported previously by heartwire , treatment of AF patients has altered dramatically in recent years with the emergence and approval of the direct thrombin inhibitor dabigatran (Pradaxa, Boehringer Ingelheim) and the oral factor Xa inhibitor rivaroxaban (Xarelto, Bayer/Johnson & Johnson).
To date, 121 000 unique AF patients are included in the registry. Of these, 50% were treated with anticoagulants in 2011. To heartwire , Oetgen, the senior vice president of science and quality at the ACC, said this number is in line with a previous analysis of AF patients treated in the PINNACLE registry. In that report, 55.1% of patients were treated with anticoagulation. In addition, the 50% anticoagulation rate is in line with other studies that assessed performance measures in patients with cardiovascular disease. For example, during the 1990s, the initial level of treating MI patients with beta blockers was approximately 45%.
"We're just starting to measure [anticoagulation rates], and there has not been time for dissemination of knowledge or for raising awareness among physicians and patients," said Oetgen. Regarding the 12.6% uptake of new oral anticoagulants, he added that physicians can be slow to change treatment patterns and are skeptical of new drugs, particularly in a therapeutic area that is fraught with danger such as AF.
"You can overdo anticoagulation and the patient gets into trouble," Oetgen told heartwire . "You can underdo it and the patient can get into trouble, too. There is a natural hesitancy. The other thing is that there have been a rash of press reports about untoward effects, or bad results, such as bleeds, probably in the range of what would be expected, but they've gotten a huge amount of press. So there's a little bit of a fear factor there."
Bristol-Myers Squibb and Pfizer provide financial support for the PINNACLE-AF registry.

Comments

Post a Comment

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...
Post a Comment
Read more

Obama Renominates Tavenner to Be CMS Chief

President Barack Obama yesterday renominated Marilyn Tavenner, the acting administrator of the Centers for Medicare & Medicaid Services (CMS), to serve in that post without the caveat of "acting" attached to it. If the Senate approves her nomination, Tavenner will be the first confirmed, full-fledged CMS administrator since Mark McClellan, MD, PhD, stepped down from that position in October 2006, during the George W. Bush administration. Dr. McClellan's successors either were acting administrators or, in the case of Donald Berwick, MD, who was Tavenner's immediate predecessor, a recess appointment. As illustrated by Dr. Berwick's  CMS history , Senate confirmation can be tough to get when one party has enough votes to filibuster and otherwise stymie a nomination by an opposing party's president. That was the case when Obama nominated Dr. Berwick, whom Senate Republicans portrayed as an advocate of healthcare rationing, a characterization denied by t...
Post a Comment
Read more

Secondary Prevention: Clinical Approaches to Managing the Higher-Risk Patient with Heart Disease

INCIDENCE/PREVALENCE/BURDENS ASSOCIATED WITH CARDIOVASCULAR DISEASE (CVD) The prevention of an initial and recurrent cardiovascular event and other complications, such as diabetes and kidney failure [also known as end-stage renal disease (ESRD) or chronic kidney disease (CKD) stage 5] is an important goal in patients with a history of CVD. Each year, approximately 185,000 Americans suffer a recurrent stroke, approximately 470,000 will have a recurrent coronary attack, and an estimated 325,000 will suffer a recurrent myocardial infarction. [1]  Secondary prevention strategies offer the opportunity to prevent further complications and improve outcomes by early detection and management of common comorbidities. The burden on public health and the costs associated with chronic illnesses such as CVD, CKD, and diabetes remain high. An estimated 82.6 million American adults (1 in 3) have 1 or more types of CVD. [1]  Heart failure is the fastest-growing clinical cardiac disease ...
Post a Comment
Read more